RecruitingPhase 3NCT07253181

Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours

Studying Acute graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Xuanwu Hospital, Beijing
Principal Investigator
Junwei Hao, MD, PhD
Xuanwu Hospital, Beijing
Intervention
Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)(drug)
Enrollment
572 target
Eligibility
18 years · All sexes
Timeline
20262028

Study locations (2)

Collaborators

Boehringer Ingelheim (China) Investment Co., Ltd · Jeffrey Saver · Maarten Lansberg · Thanh N. Nguyen · Pierre Seners · Jens Fiehler · Raul G. Nogueira

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07253181 on ClinicalTrials.gov

Other trials for Acute graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Acute graft versus host disease

← Back to all trials